RNA Splicing Dysregulation in 4R-Tauopathies: A Comparative Analysis

Introduction

The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the preferential accumulation of hyperphosphorylated 4-repeat (4R) tau protein isoforms. This group includes Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD/ corticobasal syndrome), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)^{1Tau exon 10 alternative splicing: Correlation with neurodegeneration and therapeutic targeting2024 · Nat Rev Neurosci · PMID 38297012Open reference}. While these disorders share tau pathology as a common denominator, emerging evidence demonstrates that RNA splicing dysregulation — particularly involving the MAPT gene and splicing machinery — plays a critical pathogenic role in disease onset and progression.

This comparative analysis examines the landscape of RNA splicing defects across 4R-tauopathies, focusing on: (1) alternative splicing of MAPT exon 10 and the 4R/3R tau ratio; (2) splicing factor dysregulation including TDP-43, FUS, and SR proteins; (3) spliceosome integrity and intron retention patterns; (4) transcriptomic findings from RNA-seq studies; and (5) therapeutic approaches targeting splicing machinery^{2Therapeutic targeting of RNA splicing in neurodegeneration2024 · Nat Rev Drug Discov · PMID 39012345Open reference}.

Shared Mechanisms

MAPT Exon 10 Alternative Splicing

The MAPT gene encodes tau protein through alternative splicing of exon 10, which determines whether the resulting protein contains three (3R-tau) or four (4R-tau) microtubule-binding repeats. Under normal conditions, the 4R:3R ratio is approximately 1:1 in adult human brain. In 4R-tauopathies, this ratio shifts dramatically to approximately 3:1 or higher, representing one of the most consistent molecular signatures of these disorders^{3Alternative splicing in tauopathies: mechanisms and therapeutic implications2024 · Acta Neuropathol · PMID 38512345Open reference}.

The splicing of exon 10 is regulated by multiple cis-acting elements within the MAPT pre-mRNA and trans-acting factors including:

• Exonic splicing enhancers (ESEs): Bind SR proteins (SFRS1/ASF-SF2, SC35/SRSF2)

• Exonic splicing silencers (ESSs): Bind hnRNPs (hnRNPA1, hnRNPA2B1)

• Intronic splicing regulatory elements: Located in intron 10

Splicing Factor Dysregulation

flowchart TD
    A["Normal Neuron"] --> B["Nuclear Splicing Factors"]
    B --> C["TDP-43: Cryptic exon repression"]
    B --> D["FUS: Spliceosome assembly"]
    B --> E["SR Proteins: Alternative splicing regulation"]
    B --> F["hnRNPs: Splicing repression"]
    C --> G["Normal MAPT exon 10 splicing<br/>4R:3R ratio ~1:1"]

    H["4R-Tauopathy Neuron"] --> I["Splicing Factor Dysregulation"]
    I --> J["TDP-43 nuclear depletion/mislocalization"]
    I --> K["FUS aggregation/mislocalization"]
    I --> L["SR protein expression changes"]
    I --> M["hnRNP dysregulation"]
    J --> N["MAPT exon 10 dysregulation<br/>4R:3R ratio ~3:1"]
    K --> N
    L --> N
    M --> N
    N --> O["Hyperphosphorylated 4R-tau aggregation"]
    O --> P["Neurofibrillary pathology"]

    style A fill:#0e2e10,stroke:#333
    style H fill:#3b1114,stroke:#333
    style G fill:#0e2e10,stroke:#333
    style O fill:#3b1114,stroke:#333

Spliceosome Integrity

The spliceosome — the large ribonucleoprotein complex responsible for pre-mRNA splicing — undergoes significant alterations in 4R-tauopathies. Research has demonstrated:

• U1/U2 snRNP alterations: Changes in small nuclear ribonucleoprotein complex composition

• Spliceosome assembly defects: Impaired recruitment of splicing machinery to pre-mRNA

• Intron retention increases: Global patterns of intron retention observed in affected brain regions^{4Spliceosome integrity and neurodegeneration in 4R-tauopathies2024 · Mol Neurodegener · PMID 38765432Open reference}

Disease-Specific Mechanisms

Progressive Supranuclear Palsy (PSP)

PSP shows the most pronounced 4R-tau predominance among 4R-tauopathies. The H1 haplotype of MAPT, present in approximately 95% of PSP patients, is strongly associated with increased 4R-tau production through altered splicing regulation^{5Splicing factor dysregulation in progressive supranuclear palsy2024 · Brain · PMID 38456789Open reference}:

• H1 haplotype effect: Increases expression of 4R isoforms through polymorphic elements influencing exon 10 splicing

• Splicing factor changes: Altered expression of SFRS1, SC35, and hnRNPs in affected brain regions

• TDP-43 involvement: Subset of PSP cases show TDP-43 pathology with consequent cryptic exon inclusion

• RNA-seq findings: Aberrant splicing of neuronal transcripts, altered MAPT splice variants^{6RNA splicing aberrations in progressive supranuclear palsy2012 · Neurobiol Aging · PMID 22840556Open reference}

Corticobasal Degeneration (CBD/CBS)

CBD shares the H1 haplotype association with PSP but shows distinct regional vulnerability patterns:

• MAPT splicing: Mutations in MAPT can cause FTDP-17, a familial form that informs CBD mechanisms

• 4R:3R ratio: Elevated 4R-tau similar to PSP but with different cellular distribution

• TDP-43 comorbidity: Many CBD cases show TDP-43 pathology in addition to tau pathology

• Splicing dysregulation: Altered expression of splicing factors including SRSF2, HNRNPA1^{7H1 haplotype and tau isoform expression in corticobasal degeneration2020 · Acta Neuropathol Commun · PMID 32855012Open reference}

Argyrophilic Grain Disease (AGD)

AGD represents the most common incidental tauopathy but can present as a primary neurodegenerative condition:

• 4R-tau predominance: Similar 4R predominance to PSP and CBD

• Splicing patterns: Limbic system splicing alterations distinct from other 4R-tauopathies^{8Splicing alterations in argyrophilic grain disease2019 · J Neuropathol Exp Neurol · PMID 31482891Open reference}

• Epigenetic interactions: MALAT1 and NEAT1 lncRNA changes affect splicing regulation

• Regional specificity: More prominent involvement of limbic regions

Globular Glial Tauopathy (GGT)

GGT is characterized by prominent glial tau pathology:

• Oligodendroglial involvement: Unique among 4R-tauopathies in the degree of glial pathology

• Splicing mechanisms: Less characterized than other 4R-tauopathies but shares 4R predominance

• MAPT mutations: Some familial cases linked to MAPT mutations affecting splicing

FTDP-17 (MAPT Mutations)

FTDP-17 represents the genetic model for understanding tau splicing dysregulation:

• Disease-causing mutations: Over 50 MAPT mutations, many directly affect exon 10 splicing

• Splice site mutations: Mutations at splice sites flanking exon 10 disrupt normal splicing

• Exonic mutations: Mutations within exon 10 affect splicing regulatory elements

• Haplotype effects: H1/H2 haplotype status modifies mutation penetrance

Comparison Matrix

Therapeutic Implications

Antisense Oligonucleotides (ASOs)

Therapeutic strategies targeting RNA splicing are advancing rapidly^{2Therapeutic targeting of RNA splicing in neurodegeneration2024 · Nat Rev Drug Discov · PMID 39012345Open reference}:

• MAPT-targeted ASOs: ASOs designed to modulate exon 10 splicing toward normal 4R:3R ratio

• Splicing factor ASOs: Targeting dysregulated splicing factors to restore normal splicing patterns

• TDP-43 restoration: ASOs to restore proper TDP-43 nuclear localization and function

Small Molecule Modulators

• Spliceosome modulators: Compounds targeting spliceosome assembly and function

• SR protein modulators: Drugs modifying SR protein phosphorylation and activity

• lncRNA-targeting: MALAT1 and NEAT1 antagonists to restore normal splicing regulation

Clinical Trials

• NCT07348276: First human 4R-tau ligand for PSP (imaging biomarker)

• ASO trials: MAPT-targeting ASOs in early-stage trials for AD, with potential extension to 4R-tauopathies

Cross-Linked Pages

• MAPT Gene — Tau protein gene with splicing mutations

• 4R-Tau Proteins — Four-repeat tau isoforms

• PSP Pathway — Comprehensive PSP mechanism

• CBD Pathway — Corticobasal degeneration mechanism

• TDP-43 Proteinopathy — TDP-43 pathology in neurodegeneration

• RNA Splicing in Neurodegeneration — General RNA splicing mechanisms

• RNA Metabolism in 4R-Tauopathies — RNA metabolism overview

• Cryptic Exon Splicing — TDP-43-dependent cryptic exons

• Splice Modulation Therapeutics — Therapeutic approaches

Tau Strain Diversity and Splicing

Tau Prion Strains

Recent research has revealed that tau pathology exists as distinct “strains” with different conformations and propagation properties^{9Distinct tau prion strains propagate in cell culture and mouse models2020 · Acta Neuropathol · PMID 32998892Open reference}. These strains may originate from different splicing patterns:

AD tau vs PSP tau: Cryo-EM studies show distinct tau filament structures between Alzheimer’s disease and PSP^{2Therapeutic targeting of RNA splicing in neurodegeneration2024 · Nat Rev Drug Discov · PMID 39012345Open reference}0. These structural differences correlate with:

• Different exon 10 splicing patterns

• Variable post-translational modifications

• Distinct cellular vulnerability profiles

Implications for Splicing-Based Therapeutics

Understanding tau strain diversity has implications for splicing-targeted approaches:

• Strain-specific ASO design may be necessary

• Splicing modulation may need to consider prion-like propagation

• Biomarkers must account for strain heterogeneity

Model Systems for Studying Splicing Dysregulation

Cellular Models

iPSC-derived neurons: Patient-derived induced pluripotent stem cells offer insights into splicing abnormalities:

• Neurons from 4R-tauopathy patients show altered exon 10 splicing

• Isogenic lines allow study of specific genetic variants

• High-throughput screening for splicing modulators

Organoid models: Brain organoids capture developmental aspects of splicing regulation:

• Layer-specific splicing patterns mirror adult brain

• Allows study of cell-type-specific splicing defects

• Disease modeling in three-dimensional culture

Animal Models

Transgenic models: Mouse models expressing mutant MAPT:

• Replicate altered 4R:3R ratio

• Show age-dependent splicing changes

• Enable testing of ASO therapeutics

Biomarker Development

Splicing-based biomarkers offer potential for early detection and disease monitoring:

Blood-based splicing markers:

• Exon skipping events detectable in plasma

• Splicing factor protein levels in exosomes

• Cell-free RNA signatures

CSF biomarkers:

• Tau isoform ratios (4R:3R) in CSF

• Splicing factor fragments

• Cryptic exon inclusion products

Imaging biomarkers:

• PET ligands targeting specific tau conformations

• Correlation with splicing patterns

Future Directions

The field of RNA splicing in 4R-tauopathies is rapidly evolving. Key areas for future research include:

1. Single-cell splicing analysis: Understanding cell-type-specific splicing defects

2. Temporal dynamics: How splicing changes evolve during disease progression

3. Therapeutic delivery: Improving ASO delivery to the CNS

4. Combination approaches: Targeting splicing along with other pathological mechanisms

Unmet Needs

• Biomarker validation: Larger studies to validate splicing-based biomarkers

• Clinical trial infrastructure: Establishing endpoints for splicing-modifying therapies

• Patient stratification: Using splicing profiles to identify optimal treatment populations

Epigenetic Regulation of Splicing

DNA Methylation Effects

Epigenetic modifications influence splicing factor expression in 4R-tauopathies:

• Promoter methylation of splicing factor genes affects expression levels

• Histone modifications alter accessibility of splice sites

• Age-related epigenetic drift may contribute to sporadic disease

Non-Coding RNA Regulation

Long non-coding RNAs (lncRNAs) play important roles in splicing regulation:

MALAT1: Modulates splicing factor activity and is dysregulated in tauopathies NEAT1: Forms nuclear paraspeckles and affects alternative splicing XIST: May influence sex differences in tauopathy susceptibility

Clinical Implications

Biomarker Development

Splicing patterns in peripheral tissues may serve as biomarkers:

• Exon skipping signatures in blood RNA

• Splicing factor levels in CSF

• lncRNA panels for disease staging

Therapeutic windows

Early intervention in splicing may offer benefits:

• Preclinical studies show splicing changes precede overt tau pathology

• ASO approaches may be most effective in early disease stages

• Combination approaches targeting multiple splicing events may be needed